We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

1 hedge funds and large institutions have $3.51M invested in Phio Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

30% less capital invested

Capital invested by funds: $4.98M → $3.51M (-$1.47M)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$531K
2
VKH
Virtu KCG Holdings
New York
-$167K
3
Barclays
Barclays
United Kingdom
-$8K
4
TRCT
Tower Research Capital (TRC)
New York
-$5K
5
GSC
Ground Swell Capital
South Carolina
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$2.25M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$368K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$167K – – –
CS
4
Credit Suisse
Switzerland
$163K – – –
SIM
5
Spark Investment Management
New York
$110K – – –
TCM
6
Tang Capital Management
California
$100K – – –
TAM
7
Tocqueville Asset Management
New York
$100K – – –
Jane Street
8
Jane Street
New York
$56K – – –
ARTA
9
A.R.T. Advisors
New York
$37K – – –
Northern Trust
10
Northern Trust
Illinois
$31K – – –
Bank of America
11
Bank of America
North Carolina
$28K – – –
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$28K – – –
Citadel Advisors
13
Citadel Advisors
Florida
$27K – – –
PP
14
Paloma Partners
Connecticut
$25K – – –
Group One Trading
15
Group One Trading
Illinois
$5K – – –
BIM
16
BlackRock Investment Management
Delaware
$4K – – –
Morgan Stanley
17
Morgan Stanley
New York
$2K – – –
U
18
UBS
Switzerland
$1K – – –
AIG
19
American International Group
New York
$22 – – –
Barclays
20
Barclays
United Kingdom
– -$8K – –
GSC
21
Ground Swell Capital
South Carolina
– -$1K – –
SFM
22
Sphera Funds Management
Israel
– -$531K – –
TRCT
23
Tower Research Capital (TRC)
New York
– -$5K – –
VKH
24
Virtu KCG Holdings
New York
– -$167K – –

PHIO Hedge Fund Activity: Q3 2014 in Review

1 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2014, worth a combined $3.51M — down 30% from $4.98M a quarter earlier.

Fund positioning in PHIO was balanced in Q3 2014: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Sphera Funds Management, cutting an estimated $531K.

  • 1 institutional investor held Phio Pharmaceuticals (PHIO) as of Q3 2014, unchanged from Q2 2014.
  • Funds reported $3.51M of Phio Pharmaceuticals stock for Q3 2014, down 30% quarter-over-quarter.
  • 0 funds opened new Phio Pharmaceuticals positions in Q3 2014 and 0 closed out.
  • The largest Phio Pharmaceuticals seller in Q3 2014 was Sphera Funds Management, an estimated $531K sold.

Based on aggregated 13F filings for Q3 2014.